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Abstract We report the sequence of a human cDNA that 
encodes a 46 kDa transmembrane protein homologous to 
bacterial transporters for phosphate esters. This protein presents 
at its carboxy terminus the consensus motif for retention in the 
endoplasmic reticulum. Northern blots of rat tissues indicate that 
the corresponding mRNA is mostly expressed in liver and kidney. 
In two patients with glycogen storage disease type lb, mutations 
were observed that either replaced a conserved Gly to Cys or 
introduced a premature stop codon. The encoded protein is 
therefore most likely the glucose 6-phosphate translocase that is 
functionally associated with glucose-6-phosphatase. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Glycogen storage disease type I (GSD I) is due to a defi-
ciency of glucose-6-phosphatase. This enzyme is normally 
present in the liver and the kidney, where it is located in the 
endoplasmic reticulum. According to the substrate-transport 
model, the enzymatic system comprises a hydrolase, whose 
catalytic site faces the lumen of the organelle, and various 
translocases responsible for the transport of glucose 6-phos-
phate, Pi and glucose [1-7]. The cDNAs encoding the hydro-
lase [8] and the glucose translocase [9] have been cloned, and 
the isolation of the phosphate transporter T2 has also been 
reported [10]. The putative glucose 6-phosphate transporter 
has not yet been characterized at the molecular level. Its ex-
istence has even been questioned by some authors, who inter-
pret the peculiar kinetic properties of glucose-6-phosphatase 
by a conformational model [11-13]. The most common form 
of GSD I, called type la, is due to mutations in the gene 
encoding the hydrolase [14,15], whereas a second form 
(GSD lb) has been attributed to a defect in the putative glu-
cose 6-phosphate translocase [16-18]. 
Bacteria are able to metabolize externally added phos-
phorylated compounds such as hexose 6-phosphates, glycerol 
3-phosphate and phosphoglycerate due to their ability to syn-
thesize appropriate transporters (UhpT, GlpT and PgtP, re-
spectively). These transporters all belong to the same family 
[19], which is itself a cluster in the superfamily of transmem-
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The nucleotide sequence of the cDNA described in this article is 
deposited in the EMBL database under accession number Y15409. 
brane facilitators with 12 transmembrane helices [20] and 
could therefore be homologous to liver and kidney glucose 
6-phosphate translocase. By comparison of these sequences 
with liver ESTs (expressed sequence tags), we identified a 
cDNA sequence encoding a protein of the endoplasmic retic-
ulum that is mutated in GSD lb and is, therefore, most likely 
a glucose 6-phosphate transporter. 
2. Materials and methods 
2.1. Materials 
Radioactive compounds and Thermosequenase were from Amer-
sham and Taq polymerase and Pwo polymerase, from Boehringer. 
M-MLV reverse transcriptase was from Gibco-BRL and pcDNAl/ 
Amp from Invitrogen. 
2.2. Human tissues 
Surgical biopsy specimens were obtained from two female patients 
when they were 22 (GL) or 10 (VK) years old respectively, and were 
kept at — 80°C before use. The two patients displayed typical clinical 
and laboratory symptoms of GSD lb including neutropenia. The di-
agnosis was confirmed by the finding that glucose-6-phosphatase ac-
tivity was normal in detergent-treated extracts, but reduced in homog-
enates from fresh liver and by the fact that [U-^CJglucose 6-
phosphate uptake [18] was reduced to about 10% of control values. 
Fragments of control liver, from injured subjects, were obtained from 
the liver transplantation department (Cliniques Universitaires St-Luc). 
2.3. Methods 
The =440 bp probe used in the screening of the human cDNA 
library and in the Northern blots was obtained by PCR amplification 
of mouse liver cDNA with Taq polymerase and with two primers 
designed from the EST with accession number AA261251 (GenBank): 
5'-GATCCAGGCACTAAAGAGAGCTAGC-3' and 5'-CTTGTGC-
CGGACCATTAGGAACCCA-3'. The amplified product was puri-
fied by electrophoresis in agarose gel and labelled with [a-32P]dCTP 
by random priming [21]. About 180 000 clones of a human bladder 
tumor (LB831-BLC) cDNA library (oriented, in pcDNAI/Amp, 
kindly provided by M. Guéguen and B. Van den Eynde, Ludwig 
Institute, Brussels) were screened. Four positive independent clones 
were obtained after primary and secondary screening. Restriction 
fragments were subcloned in pBlueScript for sequencing. RNA extrac-
tion and Northern blotting were performed as previously described 
[22]. 
For the search of mutations, total RNA extracted from the liver of 
patients and of controls was reverse transcribed with M-MLV reverse 
transcriptase. The 5' and 3' parts of the open reading frame of the 
human translocase were amplified by two successive rounds of ampli-
fication with nested primers (pi, p2, p5 and p6 for the 5' end; p3, p4, 
p8 and p9 for the 3' end, see Fig. 1) and with Pwo polymerase, a 
polymerase with proofreading activity. The amplified products were 
cloned in the EcoKV site of pBlueScript and sequenced. 
cDNAs were sequenced completely in both directions by the di-
deoxy method [23] with T7 Thermosequenase and IR-dye labelled 
primers. Products were analyzed using an automated laser fluores-
cence DNA sequencer 4000L from LI-COR. Multiple sequence align-
ment was performed using the program PILEUP, Wisconsin Package 
version 9.0, Genetics Computer Group, Madison, Wl. 
The QIAAmp Blood kit (QIAGEN) was used to isolate genomic 
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DNA from liver homogenates prepared in 100 mM NaCl, 0.5% SDS, 
0.1 mg/ml proteinase K, 10 mM Tris-HCl and 25 mM EDTA, pH 8.0. 
PCR was carried out with Taq polymerase. 
3. Results 
3.1. Cloning and sequencing of the human cDNA 
Using the sequence encoding the first 215 amino acids of 
the Lactobacillus lactis hexose-phosphate transporter (Gen-
Bank no. X71493), we identified a 445 bp EST from mouse 
liver (no. AA261251) encoding a homologous protein. 
Primers derived from this sequence were used to PCR-am-
plify cDNA from mouse liver, kidney, heart and brain. A 
fragment with the expected size ( ~ 440 bp) was obtained in 
all cases, though it was more abundant with liver and kidney 
cDNA than with cDNA from the other two tissues. The frag-
ment amplified from liver cDNA was used as a probe to 
screen a human cDNA library from a bladder tumor. Four 
different clones were obtained, the sequence of the longest is 
shown in Fig. 1. The second ATG codon of this sequence 
is most likely the one that is utilized for initiation of trans-
lation, since it fits much better with Kozak's consensus [24] 
than the first one. Furthermore, comparison of the human 
and the mouse nucleotide sequences indicated that a high 
degree of conservation (85% identity) started just before this 
ATG codon, whereas the upstream sequence was much less 
conserved (~51% identity), as expected for untranslated se-
quences. 
The cDNA thus encodes a 429 residue protein with a cal-
culated molecular mass of 46 329 Da. As shown in Fig. 2, the 
predicted protein is homologous to a series of bacterial trans-
porters, such as GlpT (25% identity), PgtP (21%) and UhpT 
(20%), as well as with UhpC (26%>), a membrane protein 
known to be involved in the control of UhpT expression 
and which most likely serves as a glucose 6-phosphate recep-
tor [25]. The putative human translocase is a very hydropho-
bic protein, with a hydropathy profile nearly superimposable 
to those of GlpT and UhpT (not shown). Thus, its structure is 
CAGGCTTAATGATTGTCCAGAAGGCGGCTATAAAGGGAGCCTGGGAGGCTGGGTGGAGGA 60 
GGGAGCAGAAAAAACCCAACTCAGCAGATCTGGGAACTGTGAGAGCGGCAAG£fiSGAA£X 120 pi 
GTGGTCAGAGGCTGTGrGTrtTTGGCTGGTAGGGCCTGCrpTTTTCTACCATGGCAGCCCA 180 p2 
M A A Q 4 
GGGCTATGGCTATTATCGCACTGTGATCTTCTCAGCCATGTTTGGGGGCTACAGCCTGTA 240 
G Y G Y Y R T V I F S A M F G G Y S L Y 2 4 
TTACTTCAATCGCAAGACCTTCTCCTTTGTCATGCCATCATTGGTGGAAGAGATCCCTTT 300 
Y F N R K T F S F V M P S L V E E I P L 4 4 
GGACAAGGATGATTTGGGGTTCATCACCAGCAGCCAGTCGGCAGCTTATGCTATCAGCAA 360 
D K D D L G F I T S S Q S A A Y A I S K 6 4 
GTTTGTCAGTGGGGTGCTGTCTGACCAGATGAGTGCTCGCTGGCTCTTCTCTTCTGGGCT 420 
F V S G V L S D Q M S A R W L F S S G L 8 4 
GCTCCTGGTTGGCCTGGTCAACATATTCTTTGCCTGGAGCTCCACAGTACCTGTCTTTGC 480 
L L V G L V N 1 F F A W S S T V P V F A 104 
TGCCCTCTGGTTCCTTAATGGCCTGGCCCAGGGGCTGGGCTGGCCCCCATGTGGGAAGGT 540 
A L W F L N G L A Q G L G W P P C G K V 124 
CCTGCGGAAGTGGTTTGAGCCATCTCAGTTTGGCACTTGGTGGGCCATCCTGTCAACCAG 600 
L R K W F E P S Q F G T W W A I L S T S 144 
CATGAACCTGGCTGGAGGGCTGGGCCCTATCCTGGCAACCATCCTTGCCCAGAGCTACAG 660 
M N L A G G L G P I L A T I L A Q S Y S 164 
CTGGCGCAGCACGCTGGCCCTATCTGGGGCACTGTGTGTGGTTGTCTCCTTCCTCTGTC1 720 
W R S T L A L S G A L C V V V S F L C L 184 p3 
CCTGCTrATr-.rACAATGAAC-.r-JGCTGATGTTGGACTCr.GCAACCTGGACCCCATGCCCTC 780 p4 
L L I H N E P A D V G L R N L D P M P S 204 
TGAGGGCAAGAAGGGCTCCTTGAAGGAGGAGAGCACCCTGCAGGAGCTGCTGCTGTCEEC 840 
E G K K G S L K E E S T L Q E L L L S P 224 p5 
TTACCTGTGGGTGCTCTCCACTGGT^ACCTTGTGGTGTTTGGAGTAAAGACCTGCTGTAC 900 p6 
Y L W V L S T G Y L V V F G V K T C C T 244 
TGACTGGGGCCAGTTCTTCCTTATCCAGGAGAAAGGACAGTCAGCCCTTGTAGGTAGCTC 960 
D W G Q F F L 1 Q E K G Q S A L V G S S 264 
CTACATGAGTGCCCTGGAAGTTGGGGGCCTTGTAGGCAGCATCGCAGCTGGCTACCTGTC 1020 
Y M S A L E V G G L V G S I A A G Y L S 284 
AGACCGGGCCATGGCAAAGGCGGGACTGTCCAACTACGGGAACCCTCGCCATGGCCTGTT 1080 
D R A M A K A G L S N Y G N P R H G L L 304 
GCTGTTCATGATGGCTGGCATGACAGTGTCCATGTACCTCTTCCGGGTAACAGTGACCAG 1140 
L F M M A G M T V S M Y L F R V T V T S 324 
TGACTCCCCrjVAGCTCTGGATCCTGGTATTGGGAGnTGTATTTGgTTTCTCCTCGTATGG 1200 p7 
D S P K L W I L V L G A V F © F S S Y G 344 
CCCCATTGCCCTGTTTGGAGTCATAGCCAAOBAGAGTGCCCCTCCCAACTTGTGTGGCAC 1260 
F G V A N 3 A P N G T 364 
CTCCCACGCCATTGTGGGACTCATGGCCAATGTGGGCGGCTTTCTGGCTGGGCTGCCCTT 1320 
S H A I V G L M A N V G G F L A G L P F 384 
CAGCACCATTGCCAAGCACTACAGTTGGAGCACAGCCTTCTGGGTGGCTGAAGTGATTTG 1380 
S T I A K H Y S W S T A F W V A E V I C 404 
TGCGGCCAGCACGGCTGCCTTCTTCCTCCTACGAAACATCCGCACCAAGATGGGCCGAGT 1440 
A A S T A A F F L L R N I R T K M G R V 424 
GTCCAAGAAGGCTGAGTGAAGAGAGTCCAGGTTCCGGAGCACCATCCCACGGTGGCCTTC 1500 p8 
S S K A E 429 p9 
CCCCTGrAnnrTCTGCGGGGAGAAAAGGAGGGGCCTGr.nTGGCTAGCCCTG&ACCTTTCA 1560 
CTTTCCATTTCTGCGCCTTTTCTCTCACCCGGGTGGCGCTGGAAGTTATCAGTGGCTAGT 1620 
GAGGTCCCAGCTCCCTGATCCTATGCTCTATTTAAAAGATAACCTTTGGCCTTAGACTCC 1680 
GTTAGCTCCTATTTCCTGCCTTCAGACAAACAGGAAACTTCTGCAGTCAGGAAGGCTCCT 1740 
GTACCCTTCTTCTTTTCCTAGGCCCTGTCCTGCCCGCATCCTACCCCATCCCCACCTGAA 1800 
GTGAGGCTATCCCTGCAGCTGCAGGGCACTAATGACCCTTGACTTCTGCTGGGTCCTAAG 1860 
TCCTCTCAGCAGTGGGCGACTGCTGTTGCCAATACCTCAGACTCCAGGGAAAGAGAGGAG 1920 
GCCATCATTCTCACTGTACCACTAGGCGCAGTTGGATATAGGTGGGAAGAAAAGGTGACT 1980 
TGTTATAGAAGATTAAAACTAGATTTGATACTGAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040 
Fig. 1. Sequence of the human cDNA encoding the putative transporter and deduced amino acid sequence. The stop codon and the retention 
signal for the endoplasmic reticulum are underlined. The primers are numbered pi to p9 in the right margin, and their position and direction 
are indicated by arrows under the nucleotide sequence. The two mutations (G1184T resulting in Gly339Cys and G1232T resulting in Glu355stop) 
are in shadowed characters. 
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hl h2 
UhpC MLPFLKAPAD APL-MTDKYE IDARYRYWRR HILLTIWLGY ALFYFTRKSF NAAVPEILAN GVLSRSDIGL LATLFYITYG VSKFVSGIVS DRSNARYFMG 99 
GlpT MLSIFKPAPH KAR-LPAA-E IDPTYRRLRW QIFLGIFFGY AAYYLVRKNF ALAMPYLVEQ G-FSRGDLGF ALSGISIAYG FSKFIMGSVS DRSNPRVFLP 97 
PgtP MLTILKTGQS AHK-VPPE-K VQATYGRYRI QALLSVFLGY LAYYIVRNNF TLSTPYLKEQ LDLSATQIGL LSSCMLIAYG ISKGVMSSLA DKASPKVFMA 98 
UhpT MLAFLNQVRK PTLDLPLEVR RKMWFKPFM- QSYLWFIGY LTMYLIRKNF NIAQNDMIST YGLSMTQLGM IGLGFSITYG VGKTLVSYYA DGKNTKQFLP 99 
Hums M AAQGYGYYRT VIFSAMFGGY SLYYFNRKTF SFVMPSLVEE IPLDKDDLGF ITSSQSAAYA ISKFVSGVLS DQMSARWLFS 81 
h3 h4 h5 
UhpC IGLIATGIIN ILF-GF STSLWAFAVL WVLNAFFQGW GSPVCARLLT AWYS RT ERGGWWALWN TAHNVGGALI PIV-MAAAAL HYGWR AG 186 
GlpT AGLILAAAVM LFM-GFVPWA TSSIAVMFVL LFLCGWFQGM GWPPCGRTHV HWWS QK ERGGIVSVWN CAHHVGGGIP PLLFLLGMAW FNDWH AA 189 
PgtP CGLVLCAIVN VGL-GF SSAFWIFAAL WFNGLFQGM RRP LV YYYCKLVPRR ERGRVGAFWN ISHNVGGGIV AP1VGAAFAI LGSEHWQSAS 188 
UhpT FMLILSAICM LGFSASMGSG SVSLFLMIAF YALSGFFQST GGSCSYSTIT KW TPRR KRGTFLGFWN ISHNLGGAGA AGVALFGANY LFDGH-VIGM 194 
Hums SGLLLVGLVN IFFA W SSTVPVFAAL KFLNGLAQGL GWPPCGKVLR KWF EPS QFGTWWAILS TSMNLAGGLG PIL ATI LAQSYSWRST 168 
h6 h7 
UhpC MMIAGCMAIV VGIFLCWRLR DRPQALGLPA VGEWRHDALE IAQ QQE GAGLTRKEIL TKYVLLNPYI WLLSFCYVLV YWRAAINDW GNLYMSETLG 282 
GlpT LYMPAFCAIL VALFAFAMMR DTPQSCGLPP IEEYKNDYPD DYN EKA EQELTAKQIF MQYVLPNKLL WYIAIANVFV YLLRYGILDW SPTYLKEVKH 285 
PgtP YIVPACVAVI FALIVLVLGK GSPRKEGLPS LEQMMPEEKV VLKTKNTAKA PENMSAWQIF CTYWRNKNA WYISLVDVFV YMVRFGMISW LPIYLLTVKH 288 
UhpT FIFPSIIALI VGFIGLRYGS DSPESYGLGK AEELFGEE-- -ISEEDKETE STDMTKWQIF VEYVLKNKVI WLLCFANIFL YWRIGIDQW STVYAFQELK 291 
Hums LALSGALCW VSFLCLLLIH NEPADVGLRN LDPMPSEGK- KGSLKE ESTL -QELLLSPYL WVLSTGYLW FGVKTCCTDW GQFFLIQEKG 256 
h8 h9 hlO 
UhpC VDLVTANTAV TMFELGGFIG ALVAGWGSDK L F NGNRGPMNLI FAAGILLSVG SLWLMPFASY VMQATCFF — TIGFFVFGPQ MLIGMAAAEC 372 
GlpT FALDKSSWAY FLYEYAGIPG TLLCGWMSDK V F RGNRGATGVF FMTLVTIATI VYWMNPAGNP TVDMICMI-- VIGFLIYGPV KLIGLHALEL 375 
PgtP FSKEQMSVAF LFFEWAAIPS TLLAGWLSDK L F KGRRMPLAMI CMALIFVCLI GYW—KSESL LMVTIFAA-- IVGCLIYVPQ FLASVQTMEI 376 
UhpT LSKAVAIQGF TLFEAGALVG TLLWGWLSD- L A NGRRGLVACI ALALIIATLG VY--QHASNE YIYLASLF-- ALGFLVFGPQ LLIGVAAVGF 379 
Hums QSALVGSSYM SALEVGGLVG SIAAGYLSDR AMAKAGLSNY GNPRHGLLLF MMAGMTVSMY LFRVTVTSDS PKLWILVLGA VFGFSSYGPI ALFGVIANES 356 
C * 
hll hl2 
UhpC SHKEAAGAAT GFVGLFAY-L GASLAGWP— LAKVLD TWHWSGFFW ISIAAG—IS ALLLLPFLNA QTPREA 439 
GlpT APKKAAGTAA GFTGLFGY-L GGSVAASAI- VGYTVD FFGWDGGFMV MIGGSI--LA VILLIWMIG EKRRHEQLLQ ERNGG 452 
PgtP VPSFAVGSAV GLRGFMSYIF GASLGTSLF- C 406 
UhpT VPKKAIGAAD GIKGTFAYLI GDSFAKLGLG MIADGTPVFG LTGWAGTFAA LDIAAIGCIC LMAIVAVMEE RKIRREKKIQ QLTVA 4 63 
Hums APPNLCGTSH AIVGLMAN-V GGFLAGLPFS TIA K HYSKSTAFWV AEVICAASTA AFFLLRNIRT KMGRVSKKAE 429 
Fig. 2. Sequence comparison of the human transporter with bacterial transporters for monophosphate esters. The following sequences are 
shown: glucose 6-phosphate receptor (UhpC, from E. coli [25]); transporters for glycerol 3-phosphate (GlpT, from E. coli [26]), for phospho-
glycerate (PgtP, from Salmonella typhimurium [27]) and for hexose 6-phosphates (UhpT, from E. coli [28]); human transporter (Hums). Bars 
above the alignments indicate the positions of the transmembrane helices predicted for UhpC [25]. Strictly conserved residues are in bold. The 
positions of the two mutations found in the patients are indicated by a C (for cysteine) and by an asterisk (stop). 
most likely that of a membrane protein with 12 helical trans-
membrane domains [25,29]. 
Remarkably, the encoded protein possesses at its carboxy 
terminus two lysine residues in positions —3 and —4. This 
sequence has been shown to be a signal necessary to maintain 
transmembrane proteins in the endoplasmic reticulum [30,31]. 
A similar motif is observed in the sequence of glucose-6-phos-
phatase [8]. One single potential glycosylation signal is found, 
but it is present in the loop between helices 10 and 11, which 
is predicted to be on the cytosolic side if the same topology 
applies as for UhpT and UhpC [25]. 
3.2. Northern blots 
Northern blot performed on rat tissues (Fig. 3) showed that 
a major 2.2 kb mRNA was much more abundant in liver and 
in kidney than in other tissues. A second 1.7 kb mRNA was 
mainly found in liver whereas small RNA species with sizes 
> 2.2 kb were present in other tissues. Human liver contained 
a ~ 2 kb mRNA species (not shown), which suggested that 
the cDNA shown in Fig. 1 is complete. 
from four controls using primer p9 (Fig. 1) and either a mu-
tated or a non-mutated primer (p7) with its 3' end corre-
sponding to the position of the mutated nucleotide in the 
339th codon. Amplification was observed only with the non-
mutated primer in the case of controls, only with the mutated 
primer with patient 1 and with both primers in the case of 
patient 2. Patient 1 appears therefore to be homozygous and 
patient 2 heterozygous, for the Gly339Cys mutation. In all 
cases, the size of the amplified product was 500 bp, which 
indicated the presence of a ~ 150 bp intron in this region. 
The second mutation found in patient 2 was expected to 
introduce a MaellBfal restriction site. Its presence was con-
firmed by the finding that restriction with Bfal generated a 
~ 70 bp fragment from the PCR product of genomic DNA 
amplified with the non-mutated primer p7, though not from 
that obtained with mutated p7. No such restriction was found 
with fragments amplified from four controls or from patient 1. 
These results indicated that the two mutations found in pa-
tient 2 were allelic. 
3.3. Presence of mutations in patients with GSD lb 
cDNA was prepared from the liver of two patients with 
GSD lb and the coding region of the presumed transporter 
was amplified by PCR using sets of primers spaced by about 
700 nucleotides. The amplification products were cloned and 
sequenced on both strands. One patient (GL) had a mutation 
converting an extremely conserved glycine residue (Gly339) to 
a cysteine (Figs. 1 and 2). This mutation was found in all five 
clones that were sequenced. The second patient (VC) had in 
addition to the Gly339Cys mutation (found in two clones out 
of six), a mutation that replaced Glu355 by a stop codon (in 
the four other clones). These mutations were not found in 
cDNA amplified from four controls. 
To confirm the presence of these mutations at the genomic 
level, we PCR-amplified genomic DNA from the patients and 
Fig. 3. Northern blot of rat tissues. Each lane was loaded with 25 
ug total RNA from the indicated tissues. Representative of three ex-
periments performed on different animals. 
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4. Discussion 
The cDNA reported in the present paper encodes a protein 
homologous to several bacterial proteins that are transporters 
(UhpT, GlpT and PgtP) or receptor (UhpC) for monophos-
phate esters, and which actually shares most of the residues 
that are common to these bacterial proteins. This human pro-
tein is, therefore, most likely a transporter or a receptor for a 
monophosphate ester. Due to the fact that its two closest 
homologs, UhpC and GlpT, have affinity for glucose 6-phos-
phate and glycerol 3-phosphate, respectively, it is impossible 
to deduce its specificity solely on the basis of the sequence 
data. However, the tissular distribution of this protein and 
the presence of a targeting sequence for the endoplasmic re-
ticulum are easily accounted for if one assumes that it is the 
glucose 6-phosphate translocator (or receptor) that is func-
tionally associated with glucose-6-phosphatase. 
The best proof for its identity comes from the finding that 
this protein is mutated in two patients with glycogen storage 
disease type lb. Due to the high degree of conservation of 
Gly339 (it is one of the only 30 residues that are strictly con-
served in the sequence comparison shown in Fig. 2), its re-
placement by a cysteine residue is probably incompatible with 
correct folding or function. In addition, the presence of an 
additional cysteine residue may create abnormal disulfide 
bridges. The stop codon introduced by the second mutation 
found in patient 2 not only removes the last two helices of the 
protein but also its targeting signal. Thus, even if the protein 
is functional in the absence of the last two helices, it wouldn't 
be located in the appropriate compartment for the function of 
glucose-6-phosphatase. 
The availability of the cDNA reported here will be of great 
help to define the precise function of the putative glucose 6-
phosphate transporter, i.e. if it truly acts as a transporter and 
if it is responsible for the specificity of glucose-6-phosphatase. 
It also opens the possibility of diagnosing GSD lb directly at 
the gene level. 
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